Latest news
FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer - The American Journal of Managed Care® (AJMC®)The American Journal of Managed Care® (AJMC®) · Fri, 07 Aug 2026 16:51:52 GMTFDA Clears Trodelvy as First-Line Therapy for TNBC - Clinical Oncology NewsClinical Oncology News · Thu, 06 Aug 2026 19:42:10 GMTFDA Finalizes Guidance to Broaden Cancer Trial Eligibility Criteria - Clinical Oncology NewsClinical Oncology News · Thu, 06 Aug 2026 16:59:57 GMTMSD and Gilead scrap Phase III Trodelvy-Keytruda study on lacklustre interim data - Clinical Trials ArenaClinical Trials Arena · Thu, 06 Aug 2026 10:25:17 GMTGILD Q2 Earnings Beat on HIV and Trodelvy Growth, Product Sales Outlook Raised - Yahoo FinanceYahoo Finance · Wed, 05 Aug 2026 15:22:00 GMTGILD: Q2 2026 base business grew 10% year-over-year, driven by HIV, Trodelvy, and Livdelzi - TradingViewTradingView · Tue, 04 Aug 2026 20:07:41 GMTFDA Green-Lights Five New Treatment Options for Breast Cancer - Cancer HealthCancer Health · Mon, 03 Aug 2026 13:01:12 GMTTrodelvy restores hope: ‘Even the best drug must be used at the right time’ - koreabiomed.comkoreabiomed.com · Mon, 03 Aug 2026 07:14:08 GMT